The short shelf life of platelet concentrates (PC) of up to 5–7 days leads to higher wastage due to expiry. To address this massive financial burden on the healthcare system, alternative applications for expired PC have emerged in recent years. Engineered nanocarriers functionalized with platelet membranes have shown excellent targeting abilities for tumor cells owing to their platelet membrane proteins. Nevertheless, synthetic drug delivery strategies have significant drawbacks that platelet-derived extracellular vesicles (pEV) can overcome. We investigated, for the first time, the use of pEV as a carrier of the anti-breast cancer drug paclitaxel, considering it as an appealing alternative to improve the therapeutic potential of expired PC. The pEV released during PC storage showed a typical EV size distribution profile (100–300 nm) with a cup-shaped morphology. Paclitaxel-loaded pEV showed significant anti-cancer effects in vitro, as demonstrated by their anti-migratory (>30%), anti-angiogenic (>30%), and anti-invasive (>70%) properties in distinct cells found in the breast tumor microenvironment. We provide evidence for a novel application for expired PC by suggesting that the field of tumor treatment research may be broadened by the use of natural carriers.
Nowadays, the standard media used in clinical-scale mesenchymal stem cell (MSC) production to supply hundreds of clinical trials uses animal-derived components as supplements, which raises several health concerns. Consequently, the development of xeno-free media supplements has emerged. In the current study, the effect of pulse electric field (PEF) application to platelet concentrates (PC) with no therapeutic value for producing platelet releasates (PR) able to sustain the ability of bone marrow-MSCs (BM-MSCs) to self-renew and differentiate was tested. It was demonstrated that PEF application to PC induces platelet activation and growth factor (GF) release, namely PDGF, FGF, IGF, and TGF-β. The highest GF release was observed for TGF-β, achieving similar levels to those attained in platelet lysates (PL). BM-MSCs expanded in the presence of PR obtained by the application of PEF (7 pulses of 10 and 12.5 kV/cm) to PC (PR PEF) retained the characteristic MSC cell-surface markers, and the ability to proliferate and differentiate into osteogenic, adipogenic, and chondrogenic lineages. In this study, evidence is provided that PR PEF represents a suitable alternative to fetal bovine serum (FBS) for use in MSC production.